At the recent annual San Antonio Breast Cancer Symposium (SABCS), 8 – 12 December, San Antonio, USA, the ecancerTV team caught up with Javier Cortés to discuss latest findings from the phase II SOLTI1007 study: a prospective, open-label, single-arm, exploratory pharmacogenomic study of single agent eribuilin as neoadjuvant treatment for stage I-II HER2-negative metastatic breast cancer.
The results were presented during the Symposium at Poster Session 3, Thursday 10 December: Prognostic and Predictive Factors: Response Predictions — Biomarkers and Other Factors.
To view the filmed interview and find out more please click here.
